IAInas F. Abdulrazzaq

Inas F. Abdulrazzaq

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Inas F. Abdulrazzaq has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PREPARATION AND IN VITRO EVALUATION OF CANDESARTAN CILEXETIL–BASED NANOPARTICLES AS FAST DISSOLVING ORAL FILM

    by Inas F. Abdulrazzaq, Malath H. Oudah, Abulfadhel Al-Shaibani, Yasmien A. Salal

    Objective: The present work aims to formulate candesartan cilexetil (CC) as nanoparticles oral film to enhance solubility of CC, and promote its dissolution rate, and this could produce rapid therapeutic action of drug. Methods: The nanoparticles prepared by solvent/antisolvent precipitated method then formulated as fast dissolving oral films by casting method.CC nanoparticles formulated by different polymer: drug ratio which was 1:1 and 2:1 hydroxypropyl methylcellulose (HPMC), and polyvinylpyrrolidone (PVP) with different molecular weight like, HPMCE5, HPMCE50, PVPK15 and PVPK30. The effect of polymer type, polymer ratio and injected volume on the size and specific surface area of prepared particle were tested. Results: The bested formula FCC3 was found with a smallest size equal to 37 nm and specific surface area of 54.66m2/g. The FCC3 formula was dried by freeze drier and tested by field emission scanning electron microscope (FESEM), differential scanning calorimetry (DSC) and X-ray powder diffraction analysis (XRD) to determine surface morphology, crystallinity and compatibility, then formulated as fast dissolving oral film. The drug content in the 4 cm2 prepared film was distributed between 93.00% ± 1.75 to 98.25% ± 1.25 and disintegrate in 25min. The in vitro release of candesartan nanoparticle from oral film was 68% in 2 minute and complete to 100% at 4 minutes. Conclusion: The results confirmed fast release and better dissolution rate of prepared candesartan nanoparticle than pure drug.


  • Effect of certain immunological markers on the level of anti-Müllerian hormone (AMH) in women infected with Toxoplasma gondii: further investigations

    by Sukayna Jabbar Mushattat, Jabbar Abadi Alaridi, Karrar Talib Khudhair Albo Hamrah, Salim Kadhim

    Aim: The aim of the present study is to explore the effects of T. gondii on immune levels and try to find out correlations that maybe manifest later on women who have had the infection and to assess the direct relationship between the infection and a rise in the value of anti-Müllerian hormone (AMH). Material and methods: Blood samples were collected from two identical groups of 80 (40 healthy control and 40 infected with T. gondii). The participants were women at an age ranging from 20 to 25 years; Group 1, healthy women who were not infected with Toxoplasma comprised the control series; Group 2, women who were Toxoplasma-infected and who visited medical facilities. Toxoplasma infection was diagnosed using the Latex Agglutination Test (LAT). Serum human interleukins (IL-1β and IL-6), tumor necrosis factor alpha (TNF-α) and anti-Müllerian hormone (AMH) were detected by Enzyme Linked Immunosorbent Assay (ELISA) method. Results: Compared with the control group, infected women had significantly higher levels of human IL-1 β, IL-6, and tumor necrosis factor alpha (TNF-α). AMH concentrations correlated significantly in a positive manner with human IL-1β, IL-6, and tumor necrosis factor alpha (TNF-α). Conclusions: Three immune parameters (IL-1 β, IL-6, and TNF-α) had elevated circulating levels, which implied the strong association between AMH and these immune variables.


  • Open Access

    PREPARATION AND EVALUATION OF LAFUTIDINE NANOEMULSION AS ORAL DELIVERY SYSTEM

    by Karrar T. Khudhair Albo Hamrah, Abulfadhel J. Neamah Al-Shaibani, Inas F. Abdulrazzaq

    Objective: Lafutidine is a histamine (H2) receptor antagonist utilized for the treatment of gastric ulcer. Its oral bioavailability is low due to poor water solubility and an extensive first-pass hepatic. So, the present work aims to formulate and characterize of an oil in water (o/w) nanoemulsion of lafutidine as oral liquid dosage form and this could enhance drug solubility and improve its bioavailability. Methods: The pseudo-ternary phase diagrams were constructed via titration method. The diagram plots derived from oil, various ratios of surfactant and co-surfactant (S mix), and double distilled water. The selected optimized lafutidine nanoemulsions formula was determined via a variety of investigational studies like particle size, polydispersity index (PDI), zeta potential, pH, drug content and an in vitro drug release. Results: Characterization studies revealed that the optimum formula of nanoemulsions was (NE5), which consist of 0.2% of lafutidine, 30 % of surfactant and co-surfactant (S mix) (3:1), which mean (22.5%of tween 20:7.5% of polyethylene glycol 200 (PEG 200), 10% of peppermint oil and 59.4% of double distilled water. The optimized formula exhibited droplets size (62.56-96.2 nm), PDI (0.11), good pH value (7.1), zeta potential (-32.2 mV), high drug content (99.2%), in vitro release of lafutidine was significantly higher (P<0.05) for NE5. Scanning probe microscopy (SPM) revealed that the droplets size of NE5 was in nano-scale. Conclusion: It is possible to conclude that the optimized formula (NE5) was promised formula of nanoemulsion for increasing the orally delivered lafutidine bioavailability.


  • Open Access

    Formulation and validation of Candesartan cilexetil-loaded nanosuspension to enhance solubility

    by Sarmad Al-Edresi, Karrar Albo Hamrah, Abulfadhel Al-Shaibani

    The following research aimed to enhance solubility by loading candesartan cilexetil into nanosuspension. Candesartan cilexetil-loaded nanosuspension was prepared with the aid of Design-Expert® software. A technique of solvent evaporation was employed to produce nanosuspensions from hydroxyl propyl methyl cellulose (HPMC E5), polyvinyl pyrrolidone (PVP K-30), and poloxamer (PXM 188). The optimised nanosuspensions’ particle size and polydispersity index (PDI) were 64.65 nm and 0.059, respectively. The entrapment efficacy (EE %) and drug loading (DL %) were 86.75 and 10.17%, respectively. The atomic force microscopy (AFM) revealed spherical and smooth nanoparticles. The Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) revealed pure, crystalline and conjugated drugs inside the nanosuspension. The release study confirmed 90% release within 10 min. No significant changes in particle sizes over three months were found, indicating stable nanoparticles. Saturated solubility of the candesartan cilexetil powder and loaded nanosuspension was 63.3 ± 6 and 344.7 ± 16 µg.ml-1, respectively, revealing more than five times increase in solubility. Candesartan cilexetil-loaded nanosuspensions were successfully prepared using different combinations of PVP K-30, HPMC E-5 and PXM 188 in various concentrations. Solubility was enhanced by loading the payload into nanosuspensions.


  • Open Access

    PREPARATION AND IN VITRO EVALUATION OF SELF-NANO EMULSIFYING DRUG DELIVERY SYSTEMS OF KETOPROFEN

    by Ali N. Wannas, Mazin Thamir Abdul-Hasan, Krar Kadhim Mohammed Jawad, Inas F. Abdul Razzaq

    Objective: The aim of this study was to formulate, evaluate and characterise nanoemulsion formulation containing a lipophilic drug, Ketoprofen. Methods: Nanoemulsion formulations composed of oil, surfactant, co-surfactants and Ketoprofen were prepared. In all formulations, the percent of surfactants, as well as oil, was varied while the amount of Ketoprofen kept constant. Solubility studies were conducted to select the oil, surfactant and cosurfactant. Phase diagrams were constructed using the aqueous phase titration method. Formulations were selected from the phase diagrams. The prepared nanoemulsions were subjected to different thermodynamic stability tests. Results: Following optimization, the F7 formula (10% oil, 3:1 surfactant to co-surfactant) was thermodynamically stable, with a droplet size of 105 nm and a zeta potential of-26.21 mV. In vitro release study showed that the drug release pattern from formulations F5, F6, F7, F8, F9 and F10 was higher than that of F1, F2, F3 and F4. Conclusion: The present work demonstrates that the nanoemulsion is a promising drug delivery system approach for the enhancement of solubility and dissolution rate of Ketoprofen.


  • Open Access

    A COMPARATIVE STUDY OF QUALITY CONTROL TESTING OF MEFENAMIC ACID TABLETS IN IRAQ

    by Inas F. Abdulrazzaq, Yasmien A. Salal, Mazin Thamir Abdul-Hasan, Hayder K. Abbas, Karrar Mohammed Hasan Al-Gburi

    Objective: This research was performed to assess the quality of different marketed tablets having mefenamic acid (500 mg). The selected tablets are produced by numerous companies and presented in the Iraqi pharmaceutical marketplace. Methods: Different batches of mefenamic acid conventional tablets were exposed for several tests of quality control. These evaluation tests include hardness, weight variation, friability, disintegration time, drug content, and drug dissolution profile. The properties of these quality tests were made conferring to the specification of USP-pharmacopeia. Results: The data of this study indicate that each tablet of mefenamic acid batches conformed to the requirement of USP pharmacopeia, the hardness was (6.87-8.06 Kg/cm2), and the drug content results were (90.666-99.214%) within USP limitation. The data of disintegration time and weight uniformity were agreeable with pharmacopeia and the in vitro release assay showed that the release of each mefenamic acid marketed tablet was highest than (80 %) in 45 min, which reproducing compliance with the USP pharmacopeia's limitation. Conclusion: From this study, it was proved that all of the marketed brands of mefenamic acid tablets meet the standard character in the USP pharmacopeia for in vitro quality control tests.